Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure | Zendy

Lars Gullestad | Zendy; Thor Ueland | Zendy; Jan Gunnar Fjeld | Zendy; Even Holt | Zendy; T Gundersen | Zendy; KJELL BREIVIK | Zendy; Magne Følling | Zendy; Anders Hodt | Zendy; Rita Skårdal | Zendy; John Kjekshus | Zendy; Arne K. Andreassen | Zendy; Elin Kjekshus | Zendy; Ragnhild Wergeland | Zendy; Arne Yndestad | Zendy; Stig S. Frøland | Zendy; Anne Grete Semb | Zendy; Pål Aukrust | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure

Author(s) -

Lars Gullestad,

Thor Ueland,

Jan Gunnar Fjeld,

Even Holt,

T Gundersen,

KJELL BREIVIK,

Magne Følling,

Anders Hodt,

Rita Skårdal,

John Kjekshus,

Arne K. Andreassen,

Elin Kjekshus,

Ragnhild Wergeland,

Arne Yndestad,

Stig S. Frøland,

Anne Grete Semb,

Pål Aukrust

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.564971

Subject(s) - medicine , thalidomide , ejection fraction , heart failure , cardiology , ventricular remodeling , placebo , proinflammatory cytokine , coronary artery disease , dilated cardiomyopathy , inflammation , pathology , multiple myeloma , alternative medicine

Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research